PharmAkea Therapeutics
Executives
4Board of Directors
3PharmAkea Therapeutics Management Team
4 Team Members
PharmAkea Therapeutics has 4 executives. PharmAkea Therapeutics's current President is John Hutchinson.
Name | Work History | Title | Status |
|---|---|---|---|
John Hutchinson | President | Current | |
Name | John Hutchinson | |||
|---|---|---|---|---|
Work History | ||||
Title | President | |||
Status | Current |
This profile has not been claimed.
Highlight your management team’s expertise.
PharmAkea Therapeutics Board of Directors
3 Board of directors
PharmAkea Therapeutics has 3 board of directors, including Carl Goldfischer.
Name | Firm | Work History | Other Seats |
|---|---|---|---|
Carl Goldfischer | Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme, MAP Pharmaceuticals, Metabolex, Poniard Pharmaceuticals, and PTC Therapeutics. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College. | PharmAkea Therapeutics | |
Mervyn Turner | Mervyn Turner had over 25 years of experience at Merck Research Laboratories, in research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years he was head of world-wide licensing and external research at Merck, and became Merck’s first Chief Strategy Officer and a member of the senior executive team. He retired from Merck in 2011 and currently operates his own consulting business. He serves on the Board of EnGeneIC and as an Advisor to Bay City Capital, Adagene, Bridge Medicines and the Lazard Healthcare Group. He is a member of the SAB for Spinogenix and Blade Therapeutics. | PharmAkea Therapeutics | |
Thomas Daniel | Thomas O. Daniel, M.D. has served as President, Research and Early Development of Celgene since December 2006. Prior to joining Celgene, he served as the Chief Scientific Officer and a member of the board of directors at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Dr. Daniel previously served as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Dr. Daniel received an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. | PharmAkea Therapeutics |
Name | Carl Goldfischer | Mervyn Turner | Thomas Daniel |
|---|---|---|---|
Firm | |||
Work History | Carl Goldfischer, MD, is an Investment Partner and Managing Director of Bay City Capital, serving as a member of the board of directors and executive committee, and has been with the firm since December 2000. His background includes extensive public and private investment and transaction work, as well as clinical trial development knowledge. Prior to joining Bay City Capital, Dr. Goldfischer was, until mid-2000, Chief Financial Officer of ImClone Systems where he oversaw financial operations and strategic planning. Previously, he was a Research Analyst with the Reliance Insurance Company, helping to establish its portfolio and presence in the health care investment community. Dr. Goldfischer serves on the board of directors of numerous companies, including: BrainCells, EnteroMedics, Epizyme, MAP Pharmaceuticals, Metabolex, Poniard Pharmaceuticals, and PTC Therapeutics. He received an MD with honors in Scientific Research from Albert Einstein College of Medicine, and a BA from Sarah Lawrence College. | Mervyn Turner had over 25 years of experience at Merck Research Laboratories, in research and development, licensing and business development, emerging markets analysis, and strategy development and implementation. For seven years he was head of world-wide licensing and external research at Merck, and became Merck’s first Chief Strategy Officer and a member of the senior executive team. He retired from Merck in 2011 and currently operates his own consulting business. He serves on the Board of EnGeneIC and as an Advisor to Bay City Capital, Adagene, Bridge Medicines and the Lazard Healthcare Group. He is a member of the SAB for Spinogenix and Blade Therapeutics. | Thomas O. Daniel, M.D. has served as President, Research and Early Development of Celgene since December 2006. Prior to joining Celgene, he served as the Chief Scientific Officer and a member of the board of directors at Ambrx Inc., a biotechnology company focused on discovering and developing protein-based therapeutics. Dr. Daniel previously served as Vice President, Research at Amgen Inc., where he was Research Site Head of Amgen Washington and Therapeutic Area Head of Inflammation. Dr. Daniel received an M.D. from the University of Texas, Southwestern, and completed medical residency at Massachusetts General Hospital. |
Other Seats | PharmAkea Therapeutics | PharmAkea Therapeutics | PharmAkea Therapeutics |
Discover the right solution for your team
The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.